Anavex Life Sciences Corp
AVXL7.900USD
0.0000.00%
收盤 10/31, 16:00（美東）報價延遲15分鐘
674.75M總市值
虧損本益比TTM
關於 Anavex Life Sciences Corp 公司
Anavex Life Sciences Corp. 是一家臨牀階段的生物製藥公司，致力於通過將精準醫療應用於具有高度未滿足需求的中樞神經系統 (CNS) 疾病來開發差異化療法。該公司分析臨牀試驗的基因組數據以識別生物標記物，並將其用於臨牀試驗分析。其重點是開發阿爾茨海默病、帕金森病、精神分裂症、神經發育、神經退行性疾病和罕見疾病（包括雷特綜合徵）和其他中樞神經系統疾病的治療方法。該公司有兩個核心項目和兩個種子項目。ANAVEX 2-73 正在開發爲用於治療雷特綜合徵等罕見疾病的口服液體每日一次配方，以及用於治療阿爾茨海默病等疾病的口服每日一次膠囊配方。ANAVEX 3-71 是一種可穿透中樞神經系統的潛在疾病修飾療法，用於治療認知障礙。其其他候選藥物包括 ANAVEX 1-41、ANAVEX 1066 和 ANAVEX 1037。
Anavex Life Sciences Corp簡介
公司代碼AVXL
公司名稱Anavex Life Sciences Corp
上市日期Apr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
員工數量42
證券類型Ordinary Share
年結日Apr 13
公司地址630 5Th Avenue
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10111
電話18446893939
網址https://www.anavex.com
公司代碼AVXL
上市日期Apr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Anavex Life Sciences Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
其他
78.96%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
其他
78.96%
股東類型
持股股東
佔比
Investment Advisor
23.94%
Investment Advisor/Hedge Fund
9.52%
Individual Investor
3.36%
Hedge Fund
3.04%
Research Firm
1.10%
Bank and Trust
0.83%
Pension Fund
0.21%
Insurance Company
0.04%
其他
57.97%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
365
33.21M
38.67%
-1.68M
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
6.22M
7.24%
+237.96K
+3.98%
Jun 30, 2025
The Vanguard Group, Inc.
5.09M
5.92%
+204.62K
+4.19%
Jun 30, 2025
State Street Investment Management (US)
2.95M
3.43%
-265.45K
-8.26%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.02M
2.35%
+54.98K
+2.80%
Jun 30, 2025
Two Sigma Investments, LP
1.80M
2.09%
+428.37K
+31.31%
Jun 30, 2025
Missling (Christopher U)
1.51M
1.76%
+42.45K
+2.89%
Sep 11, 2025
Skarpelos (Athanasios)
1.31M
1.52%
--
--
Apr 25, 2025
Northwest Asset Management
1.02M
1.19%
+24.13K
+2.41%
Jun 30, 2025
Invesco Capital Management LLC
821.33K
0.96%
+306.26K
+59.46%
Jun 30, 2025
Northern Trust Investments, Inc.
715.06K
0.83%
+40.31K
+5.97%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
1.32%
ALPS Medical Breakthroughs ETF
0.42%
SPDR S&P Biotech ETF
0.25%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Growth ETF
0.05%
查看更多
iShares Neuroscience and Healthcare ETF
佔比1.32%
ALPS Medical Breakthroughs ETF
佔比0.42%
SPDR S&P Biotech ETF
佔比0.25%
iShares Micro-Cap ETF
佔比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.14%
Vanguard US Momentum Factor ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.08%
Invesco Nasdaq Biotechnology ETF
佔比0.08%
iShares Biotechnology ETF
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
